KYBORA Successfully Helps STADA License Xlucane to Bausch Health

Homepage
About Us
Services
News Feed
Contact
English
- English
- 中文

Homepage
About Us
Services
News Feed
Contact
English
- English
- 中文

KYBORA Successfully Helps STADA License Xlucane to Bausch Health

February 26, 2020

No comments

News

KYBORA Successfully Helps STADA License Xlucane to Bausch Health

About the author.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Save my name, email, and website in this browser for the next time I comment.

Recent blog post.

The Foundation Rwanda KYBORA Initiative – Meet Paulin Nkusi

Posted: 3 days ago
Brazil’s Specialty Pharmaceutical Market Surges 250%. Projected to overtake Canada, Spain, Italy, and the United Kingdom and become the 6th largest market in the world in 2024

Posted: 3 weeks ago
Medicamentos de Especialidade Crescem 250% no Brasil. Projetado a ultrapassar Canadá, Espanha, Itália e Reino Unido em 2024 e tornar-se no 6º maior mercado do mundo em 2024

Posted: 3 weeks ago
KYBORA releases a Chinese version of its website to accelerate its growth in Asia

Posted: 3 weeks ago
How is the Inflation Reduction Act affecting biotech investment?

Posted: 1 month ago

Tags.

#biopharma Licensing Announcement Bausch Health biopharma biotechnology China Conference Corporate globalhealthcare healthtech Kybora Team LIcensing March 2020 mergersandacquisitions News Priority List Stada license

Tell us about your business and corporate development needs.

Contact Us

Kybora is a global advisory firm whose mission is to help life sciences companies achieve enduring success by offering optimal M&A, licensing, fundraising and strategic consulting services in all key markets around the world.

About Us.

About Kybora
Meet our team
Success Story
Our Global Presence

Our Services.

M&A
Licensing
Fundraising
Strategic Consulting

Latest News Feed.

The Foundation Rwanda KYBORA Initiative – Meet Paulin Nkusi

Posted: 3 days ago
Brazil’s Specialty Pharmaceutical Market Surges 250%. Projected to overtake Canada, Spain, Italy, and the United Kingdom and become the 6th largest market in the world in 2024

Posted: 3 weeks ago

Terms of service | Privacy policy

KYBORA Successfully Helps STADA License Xlucane to Bausch Health

About the author.

Drcom Content Editor

administrator

No Comments. Leave a comment

Leave a Reply Cancel reply

Recent blog post.

The Foundation Rwanda KYBORA Initiative – Meet Paulin Nkusi

Brazil’s Specialty Pharmaceutical Market Surges 250%. Projected to overtake Canada, Spain, Italy, and the United Kingdom and become the 6th largest market in the world in 2024

Medicamentos de Especialidade Crescem 250% no Brasil. Projetado a ultrapassar Canadá, Espanha, Itália e Reino Unido em 2024 e tornar-se no 6º maior mercado do mundo em 2024

KYBORA releases a Chinese version of its website to accelerate its growth in Asia

How is the Inflation Reduction Act affecting biotech investment?

TYPE & ENTER: